Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 562-566

  Zhang, Zhen ^a   Zhang, Keke ^a   Du, Xinrui ^a   Li, Yanbin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Desferrioxamine; Inflammation; Lipopolysaccharide; Parkinson's disease

Indexed keywords

DEFEROXAMINE; IRON; LIPOPOLYSACCHARIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; LIPOPOLYSACCHARIDE INDUCED NIGROSTRIATAL DOPAMINE NEURON DEGENERATION; MALE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ANIMAL; DEFEROXAMINE; DOPAMINERGIC NEURONS; IRON; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; VISUAL CORTEX;

ANIMALIA; MUS;

EID: 84862912266     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.671     Document Type: Article

References (31)

1. Hornykiewicz O: Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 60: 140-147, 1993.
2. Youdim MB and Riederer P: Understanding Parkinson's disease. Sci Am 276: 52-59, 1997.
3. Sofic E, Riederer P, Heinsen H, et al: Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J Neural Transm 74: 199-205, 1988.
4. Kaur D, Yantiri F, Rajagopalan S, et al: Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909, 2003. (Pubitemid 36398297)
5. Salazar J, Mena N, Hunot S, et al: Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 105: 18578-18583, 2008.
6. Mastroberardino PG, Hoffman EK, Horowitz MP, et al: A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis 34: 417-431, 2009.
7. Snyder AM and Connor JR: Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790: 606-614, 2009.
8. Lee DW, Rajagopalan S, Siddiq A, et al: Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 284: 29065-29076, 2009.
9. Song N, Wang J, Jiang H and Xie J: Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease. Free Radic Biol Med 48: 332-341, 2010.
10. Double KL and Halliday GM: New face of neuromelanin. J Neural Transm 70: S119-S123, 2006.
11. Dong XP, Cheng X, Mills E, et al: The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 455: 992-996, 2008.
12. Johansson AC, Appelqvist H, Nilsson C, Kagedal K, Roberg K and Ollinger K: Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15: 527-540, 2010.
13. Mandel S, Weinreb O, Amit T and Youdim MB: Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3- gallate: implications for neurodegenerative diseases. J Neurochem 88: 1555-1569, 2004. (Pubitemid 38366932)
14. Zhu W, Xie W, Pan T, et al: Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844, 2007. (Pubitemid 350232341)
15. Zhang X, Xie W, Qu S, Pan T, Wang X and Le W: Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun 333: 544-549, 2005. (Pubitemid 40848325)
16. McGeer PL, Yasojima K and McGeer EG: Inflammation in Parkinson's disease. Adv Neurol 86: 83-89, 2001.
17. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B and Hong JS: Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 20: 6309-6316, 2000. (Pubitemid 30658427)
18. Hunter RL, Cheng B, Choi DY, et al: Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87: 1913-1921, 2009.
19. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW and Johnson JA: Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 102: 244-249, 2005. (Pubitemid 40094460)
20. Li C, Biswas S, Li X, Dutta AK and Le W: Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine and lactacystin. J Neurosci Res 88: 2513-2523, 2010.
21. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W and Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31: 1081-1092, 2011.
22. Jung BD, Shin EJ, Nguyen XK, et al: Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56: 229-244, 2010.
23. Choi DY, Liu M, Hunter RL, et al: Striatal neuroinflammation promotes Parkinsonism in rats. PLoS One 4: e5482, 2009.
24. Hirsch EC and Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397, 2009.
25. Castano A, Herrera AJ, Cano J and Machado A: Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70: 1584-1592, 1998. (Pubitemid 28136972)
26. Hunter RL, Dragicevic N, Seifert K, et al: Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100: 1375-1386, 2007.
27. Saijo K, Winner B, Carson CT, et al: A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137: 47-59, 2009.
28. Gotz ME, Double K, Gerlach M, Youdim MB and Riederer P: The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci 1012: 193-208, 2004. (Pubitemid 38455479)
29. Hallgren B and Sourander P: The effect of age on the non-haemin iron in the human brain. J Neurochem 3: 41-51, 1958.
30. Berg D, Becker G, Riederer P and Riess O: Iron in neurodegenerative disorders. Neurotox Res 4: 637-653, 2002. (Pubitemid 35385963)
31. Gutteridge JM: Iron and oxygen radicals in brain. Ann Neurol 32: S16-S21, 1992.